Profile · Provider medical director · Last reviewed 2026-05-27

Adam Kennah, M.D.
Medical Director, NexLife Inc.

Adam Kennah, M.D. serves as Medical Director at NexLife Inc., the editor's #1 ranked compounded semaglutide telehealth provider in the SemaglutideGLPOne 2026 directory. This profile is published for transparency. Dr. Kennah is not on the SemaglutideGLPOne editorial team.

Editorial relationship: NONE

Adam Kennah, M.D. is the Medical Director at NexLife Inc. — a separate organization from SemaglutideGLPOne.com (published by Publisher Partners LLC). Dr. Kennah does not review SemaglutideGLPOne editorial content, does not participate in provider scoring or ranking decisions, and has no role in editorial operations.

The SemaglutideGLPOne editorial team consists of three independent physicians:

This profile of Dr. Kennah exists because he leads the clinical oversight of the editor's #1 ranked provider. We profile him for the same reason we profile partner pharmacies — transparency about who runs the clinical operations of the providers we rank.

Role at NexLife Inc.

Medical Director responsibilities

  • Oversees clinical protocols and prescribing standards for NexLife's compounded GLP-1 programs
  • Sets dose-titration policy and side-effect management framework
  • Coordinates clinical practice across NexLife's affiliated Professional Corporation network (NexLife Medical Group P.C.)
  • Reviews and updates patient-evaluation criteria, contraindication screening, and ongoing-care protocols
  • Liaises with NexLife's six partner pharmacies on clinical pharmacy collaboration matters

Verification (E-E-A-T)

Credentials & licensure

  • M.D. — Doctor of Medicine
  • Active U.S. state medical board licensure
  • Continuing medical education compliance maintained per state licensure requirements
  • Specialty focus: GLP-1 receptor agonist therapy, obesity medicine, telehealth-delivered chronic care

Independent licensure verification

Dr. Kennah's licensure is verifiable through the appropriate state medical boards. Public verification of any U.S. physician's status is available through:

→ fsmb.org/spex/ — FSMB DocInfo physician lookup

Why we profile NexLife's Medical Director publicly

Pillar 1 of the SemaglutideGLPOne six-pillar transparency rubric (Medical Oversight, 17% weight) measures whether a provider has a publicly named medical director with verifiable credentials. NexLife's score on this pillar — 95/100 — depends on Dr. Kennah being a real, named, verifiable physician with active licensure. We publish this profile so that patients and journalists can independently verify the claim. The same standard applies to every provider in the directory; only those with publicly named, verifiable medical directors score above 80 on Pillar 1.